REALIZATION OF REPRODUCTIVE OPPORTUNITIES AND PROLONGATION OF REMISSION OF UTERINE FIBROIDS AFTER SURGICAL TREATMENT


DOI: https://dx.doi.org/10.18565/pharmateca.2018.6.36-42

S.V. Apresyan (1, 2), V.I. Dimitrova (1), O.A. Slyusareva (1), V.A. Lyubeshkina (1), T.G. Mustafaeva (1)

1 City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare Department, Moscow, Russia; 2 Peoples’ Friendship University of Russia, Moscow, Russia
Objective. Assessment of the realization of reproductive opportunities and the frequency of recurrence of the disease in patients who underwent organ-preserving treatment for uterine fibroids (UFs) and a course of adjuvant therapy with mifepristone (Gynestril) for two years after drug discontinuation. Methods. A cohort prospective comparative study included 136 women who underwent organ-preserving treatment (myomectomy or uterine artery embolization) for UFs. Mifepristone was administered at a dose of 50 mg/day
(1 tablet) starting from the 1 day of the menstrual cycle after surgical treatment in a continuous mode for 3 months, taking into account contraindications to its use. Results. It was shown that the use of mifepristone in continuous mode after surgical treatment for proliferative UFs led to the absence of relapses of the disease within two years after drug discontinuation. The use of mifepristone after uterine artery embolization significantly reduced node size by 25% at 12 months and by 50% (p<0.05) at 24 months. Complex treatment of UFs, including myomectomy and drug therapy with mifepristone, allowed to realize reproductive function in 46% of patients.
Conclusion. Long-term results of the study make it possible to recommend mifepristone in the postoperative period for patients who underwent organ-preserving treatment for proliferating UFs in order to prevent recurrence of the disease within 24 months after drug discontinuation.

About the Autors


Corresponding author: S.V. Apresyan – MD, Prof. at the Department of Obstetrics and Gynecology with the Course of Perinatology of the Peoples’ Friendship University of Russia, Deputy Chief Physician for Obstetric and Gynecological Care, City Clinical Hospital n.a. F.I. Inozemtsev of the Moscow Healthcare Department, Moscow, Russia; e-mail: sapresyan@mail.ru


Similar Articles


Бионика Медиа